Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Amsterdam Molecular Falls as Much as 58% After EMA Decision

Oct. 21 (Bloomberg) -- Amsterdam Molecular Therapeutics Holding NV fell as much as 58 percent in Amsterdam trading after a European Medicines Agency panel said the company’s Glybera therapy for the genetic disorder disorder lipoprotein lipase deficiency wasn’t approvable at this time.

Link to Company News:{AMT NA <Equity> CN <GO>}

To contact the editor responsible for this story: Kristen Hallam at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.